Oral antiplatelet therapy with aspirin and clopidogrel is a major strategy to prevent
thrombotic events in patients with acute coronary syndromes and patients undergoing …

Methods From Korea Acute Myocardial Infarction Registry-National Institute of Health
database, 1,819 patients treated with DES who were switched to monotherapy with …

Among patients who have undergone percutaneous coronary intervention (PCI), the use of
dual antiplatelet therapy (DAPT) is associated with increased risk of bleeding, but decreased …

Background Dual antiplatelet therapy (DAPT) for 12 months is recommended in patients with
drug-eluting stent (DES) implantation. However, there are few studies compared between …

BACKGROUND: Patients presenting with acute coronary syndrome are administered a P2Y
12 inhibitor and aspirin before coronary catheterization to prevent further myocardial injury …

Background—After coronary artery bypass surgery, patients have a high cumulative rate of
graft closure and recurrent ischemic events. We sought to determine whether antiplatelet …

Background This study estimates the temporal risk variations of ischemic and bleeding
events during dual antiplatelet therapy (DAPT) among patients stratified according to the …

Background—Uncertainty exists about the frequency, correlates, and clinical significance of
bleeding with dual antiplatelet therapy (DAPT), particularly over an extended period in a …

Continuation of dual antiplatelet therapy (DAPT) beyond 1 year reduces late stent
thrombosis and ischemic events after drug‐eluting stents (DES) but increases risk of …

Background: There is controversy among physicians regarding the use of dual antiplatelet
therapy (DAPT) in acute coronary syndrome (ACS) patients treated with coronary artery …